NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines

NHS Greater Glasgow and Clyde Area Drug and Therapeutics Committee

 

NHS Greater Glasgow & Clyde

GGC Medicines

 

 

GGC Medicines has been designed as a tool to assist in promoting high quality, safe and cost-effective prescribing within the Greater Glasgow and Clyde Health Board.  The website has useful resources for prescribers and patients including:

  • The GGC Adult Medicines Formulary as a searchable or navigational database
  • The Adult Therapeutics Handbook: an essential resource for junior medical staff working in NHSGGC
  • Current prescribing and clinical information via the Medicines Update suite of publications
  • Information for patients on access to medicines
  • Policies relating to medicines in NHSGGC
  • Other formularies

Latest news:

GGC Medicines App is currently unavailable from the App Store and Google Play but will be back soon:


  • To comply with EU Medical Device Regulations, GGC Medicines has been temporarily taken off market while the app is further updated to ensure that it is only for use within NHS Greater Glasgow and Clyde (i.e. password protected)
  • In the interim, this will not affect those NHSGGC staff who have already downloaded the app and it can continued to be used
  • When the app is updated and available for download again, users will be requested to enter a username and password to complete the installation process.  These details can be accessed from the Clinical Info page of StaffNet (only accessible to NHSGGC staff with access to the Health Board intranet)
  • In the longer-term, registration of the app as a CE marked Medical Device is being progressed

 

 

CURRENT ALERTS:

 

HYDROXYZINE (April 2015): The MHRA published adice relating to hydroxyzine advising that the maximum adult daily dose is now 100mg and advising that, due to the risk of QT interval prolongation and Torsade de Pointes, it should not be prescribed to people with prolonged QT interval or risk factors for QT interval prolongation. For further information, see the MHRA guidance.

DOMPERIDONE (April 2014): Following a Europe-wide review, the MHRA issued advice to healthcare professionals relating to the use of domperidone, restricting its use to relief or nausea and vomiting, advising that it should be used at the lowest effective dose for the shortest possible time, and highlighting changes to the contraindications, dosing and duration of treatment of the medicine. The full advice from the MHRA can be accessed here.